This 2011 Lancet narrative review by Rachner, Khosla, and Hofbauer maps the molecular biology of osteoblast-osteoclast communication to explain how novel therapeutic targets were identified. It covers three antiresorptive mechanisms (RANKL inhibition, cathepsin K inhibition, Src kinase inhibition) and two anabolic strategies (sclerostin antibody, Dkk-1 antibody), with clinical trial data available at the time of publication.
This 2011 Lancet narrative review by Rachner, Khosla, and Hofbauer maps the molecular biology of osteoblast-osteoclast communication to explain how novel therapeutic targets were identified. It covers three antiresorptive mechanisms (RANKL inhibition, cathepsin K inhibition, Src kinase inhibition) and two anabolic strategies (sclerostin antibody, Dkk-1 antibody), with clinical trial data available at the time of publication.